trimetrexate has been researched along with Melanoma in 2 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Melanoma: A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trimetrexate glucuronate, a nonclassical antifolate, was administered to 14 patients with recurrent and progressive metastatic malignant melanoma." | 7.68 | Treatment of metastatic malignant melanoma with trimetrexate: a phase II study. ( Akman, S; Carr, B; Doroshow, J; Goldberg, D; Grove, W; Leong, L; Margolin, K; Odujinrin, O, 1990) |
| "The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy." | 7.68 | Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study. ( Bodurtha, AJ; Eisenhauer, EA; Iscoe, NA, 1990) |
| "Trimetrexate glucuronate, a nonclassical antifolate, was administered to 14 patients with recurrent and progressive metastatic malignant melanoma." | 3.68 | Treatment of metastatic malignant melanoma with trimetrexate: a phase II study. ( Akman, S; Carr, B; Doroshow, J; Goldberg, D; Grove, W; Leong, L; Margolin, K; Odujinrin, O, 1990) |
| "The National Cancer Institute of Canada Clinical Trials Group carried out a phase II trial of trimetrexate given in a daily x 5 intravenous bolus schedule every 3 weeks in patients with measurable metastatic malignant melanoma who had not received previous chemotherapy." | 3.68 | Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study. ( Bodurtha, AJ; Eisenhauer, EA; Iscoe, NA, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Odujinrin, O | 1 |
| Goldberg, D | 1 |
| Doroshow, J | 1 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Grove, W | 1 |
| Carr, B | 1 |
| Akman, S | 1 |
| Iscoe, NA | 1 |
| Eisenhauer, EA | 1 |
| Bodurtha, AJ | 1 |
2 other studies available for trimetrexate and Melanoma
| Article | Year |
|---|---|
Treatment of metastatic malignant melanoma with trimetrexate: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Folic Acid Antagonists; Humans; Male; M | 1990 |
Phase II study of trimetrexate in malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group study.
Topics: Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Folic Acid Antagonists; Hematolo | 1990 |